Processa Pharmaceuticals, Inc. (PCSA) Operating cash flow 2016–2025
Processa Pharmaceuticals, Inc. (PCSA) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$11.4MFY2025 · since FY2016: -$2.2M → -$11.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$11.4M | -1.2% |
| FY2024 | -$11.2M | -39.5% |
| FY2023 | -$8.1M | +16.1% |
| FY2022 | -$9.6M | -10.2% |
| FY2021 | -$8.7M | -177.3% |
| FY2020 | -$3.1M | -14.3% |
| FY2019 | -$2.8M | +25.8% |
| FY2018 | -$3.7M | -124.1% |
| FY2017 | -$1.7M | +23.2% |
| FY2016 | -$2.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PCSA financial trends
PCSA RevenuePCSA Net incomePCSA Net marginPCSA Gross profitPCSA Gross marginPCSA Operating incomePCSA Operating marginPCSA Free cash flowPCSA Capital expendituresPCSA Return on equityPCSA Stock buybacksPCSA Dividends paidPCSA Total assetsPCSA Total liabilitiesPCSA Shareholders’ equityPCSA overview →